Showing results (371-380 of 500) with videos related to
Sort By:
Pageof 50
Journal of Neuro-Oncology|October 24, 2015
Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experienceBrandon S Imber, Steve E Braunstein, Fred Y Wu, et al.Neuroimage. Clinical|July 6, 2020
Characterization of serial hyperpolarized 13C metabolic imaging in patients with gliomaAdam W Autry, Jeremy W Gordon, Hsin-Yu Chen, et al.NPJ Digital Medicine|August 7, 2025
Novel radiotherapy target definition using AI-driven predictions of glioblastoma recurrence from metabolic and diffusion MRINate Tran, Tracy L Luks, Yan Li, et al.Neuroimage. Clinical|August 23, 2023
Multi-parametric hyperpolarized 13C/1H imaging reveals Warburg-related metabolic dysfunction and associated regional heterogeneity in high-grade human gliomasAdam W Autry, Sana Vaziri, Marisa LaFontaine, et al.Cell Reports|March 29, 2018
Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma ProliferationHarish N Vasudevan, Steve E Braunstein, Joanna J Phillips, et al.Neurosurgery|January 4, 2022
Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type GlioblastomaAlexander A Aabedi, Jacob S Young, Yalan Zhang, et al.Journal of the American College of Radiology : JACR|May 23, 2025
ACR Appropriateness Criteria® Brain Tumors, Jana Ivanidze, Robert Y Shih, et al.Neuro-Oncology Practice|March 9, 2026
Tele-cognitive rehabilitation for adult lower-grade glioma: An interim prospective pilot feasibility studyChristina Weyer-Jamora, Melissa S Brie, Paige M Bracci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2019
Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons GuidelinesSusan M Chang, Hans Messersmith, Manmeet Ahluwalia, et al.Neuro-Oncology|September 8, 2011
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcomaNicholas Butowski, Susan M Chang, Kathleen R Lamborn, et al.Pageof 50